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• As far as we are aware, this is the first-ever reported observation of EEG 
characteristics specific to N3 sleep stages.
• The observation of a hemispheric (asymmetrical) effect in EEG power in 
specific leads is notable. In sleep, activity should be symmetrical. Why is 
activity instead different in one hemisphere versus the other?
• The resolution of these OSA power differences with CPAP treatment could 
potentially be offered as evidence supporting the efficacy of this treatment.
• These findings suggest that EEG alone could be used as a reliable 
biomarker for OSA, potentially eliminating the need for time-intensive and 
costly polysomnography tests for OSA.
SIGNIFICANCE
• Obstructive sleep apnea (OSA) is the most common sleep disorder, 
affecting 13% of men and 6% of women in the U.S.
• The incidence of OSA has increased 300% in last 20 years.
• OSA not only causes excessive daytime sleepiness, decreased work 
productivity, and reduced quality of life, but also increases patients’ risks 
for hypertension, stroke, heart failure and atrial fibrillation.
• Currently, the gold standard for OSA diagnosis is polysomnography (PSG), 
which requires patients to be monitored continuously throughout a single 
night of sleep.
• Due to the length of this monitoring process, undiagnosed patients have 
been forced to wait for 3-4 months to undergo PSG.
• Shortening this monitoring process would enable patients with OSA to be 
identified and treated earlier.
BACKGROUND
METHODS
The EEG [first 2 epochs of N3 (Stage 3 Non-REM) sleep] data from 8 
healthy controls and 8 patients with OSA before and after CPAP treatment 
was obtained from the Sleep Disorders Clinic at the University Hospital, 
(Columbia, MO) and subjected to spectral analysis (Spike2 software; 
Cambridge Electronic Design, Cambridge, UK), yielding total power in the 
following bands: 
• 1 Hz to 3.9 Hz (Delta)
• 4 Hz to 8.9 Hz (Theta)
• 9 Hz to 12 Hz  (Alpha)
• 1 Hz to 50 Hz  (Total)
These frequency bands were analyzed at standard EEG leads. 
To minimize variability, the data was normalized by calculating  "relative 
power" (defined as the total power in each band divided by the total power; 
1-50 Hz) which was used for further analysis. One way ANOVA and LSD 
post-hoc statistical tests were then conducted comparing the relative powers 
of each band between the three groups.
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PURPOSE
• This study compared electroencephalogram (EEG) spectral analysis data 
between healthy subjects and patients with OSA before and after 
treatment with continuous positive airway pressure (CPAP).
• We sought to identify biomarkers that may aid in identifying, predicting, 
and monitoring OSA disease progression using EEG spectral power.
• The goal of this study was to identify EEG patterns characteristic of sleep 
apnea within the initial phases of specific stages of sleep.
RESULTS
Figure 1. Frequency band analysis showing differences in EEG spectral 
power between leads during N3 sleep. A: Healthy control (sample of 
recording; differences not notable). B: Untreated OSA (sample of recording; 
visual differences between C3 and C4). 1C: CPAP-treated OSA (sample of 
recording; differences not notable).
SALIENT FINDINGS
• The initiation of stage N3 sleep is measurably different in OSA patients 
before and after treatment, with significant differences primarily appearing 
in left-sided leads, but not right-sided leads.
• Treatment with CPAP corrects these differences, so that both healthy and 
CPAP-treated OSA patients do not show differences in either the left-sided 
or the right-sided leads.
• In untreated OSA patients vs. healthy patients, the changes in spectral 
power are marked by a decrease in theta band power concomitant with an 
increase in delta band power.
• Unlike the other left-sided leads, the F3 lead did not show significant 
differences in OSA patients. Therefore, although differences are 
exclusively left-sided, they are not found in all left-sided leads.
• No significant differences in alpha band power were seen in any leads.
p<0.05
p<0.05
p<0.05 p=0.08
Figure 2. Significant differences in mean relative power between healthy 
controls and OSA patients and without CPAP treatment. Note: As compared 
to healthy controls, the OSA group displayed a simultaneous reduction in 
delta power and an increase in theta power. Changes in spectral power in all 
bands returned to normal values after CPAP treatment. 
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Figure 3. Frequency band 
analysis demonstrating a 
hemispheric effect in spectral 
power in OSA patients as 
compared to healthy controls 
and after CPAP treatment. 
Green: Statistically significant 
(p<0.05). Yellow: Trend-level 
significance (0.05<p<0.1). 
White: No difference (p>0.1).
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